Programmable elution profile coating for drug eluting stents.
Despite good results in reducing in-stent restenosis during cardiac stenting procedures, a number of issues in the application of drug-eluting stents still challenge the industry. These include drug-elution kinetics and long-term biocompatibility. Some of the latest developments in these areas are described here.
Al-Lamee
K
K
Lombard Medical Technologies plc, Sheffield, UK. kadem.allamee@lombardmedical.com
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage* / Q000737:chemistry; D004343:Drug Implants / Q000008:administration & dosage* / Q000737:chemistry; D006083:Graft Occlusion, Vascular / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D015607:Stents / Q000009:adverse effects*; D013499:Surface Properties
D000893:Anti-Inflammatory Agents; D020099:Coated Materials, Biocompatible; D004343:Drug Implants